drugset / Trial / NCT00845039
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
Timeline
- Start
- 2009-05
- Primary completion
- 2011-02
- Completion
- 2011-02
Outcome
Outcome not reported
Stopped (Business): “Study terminated early 22Feb2010 with only 4 participants due to business reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Cixutumumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |